Pioglitazone Lowers Systemic Asymmetric Dimethylarginine by Inducing Dimethylarginine Dimethylaminohydrolase in Rats

No abstract is available for this paper.

• Publication year

  2005

• Venue

  Hypertension Research

• Publication date

  2005-03-01

• Fields of study

  Biology, Medicine, Chemistry

• Identifiers
  DOI 10.1291/hypres.28.255PMID 16097370
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Peroxisome Proliferator-Activated Receptor γ Ligands Inhibit Rho/Rho Kinase Pathway by Inducing Protein Tyrosine Phosphatase SHP-2

  2004cited by this paper
• Pioglitazone Prevents Hypertension and Reduces Oxidative Stress in Diet-Induced Obesity

  2004cited by this paper
• Expression of peroxisome proliferator-activated receptor isoform proteins in the rat kidney.

  2004cited by this paper
• Partial gene deletion of endothelial nitric oxide synthase predisposes to exaggerated high-fat diet-induced insulin resistance and arterial hypertension.

  2004cited by this paper
• NO dependency of RBF and autoregulation in the spontaneously hypertensive rat.

  2003cited by this paper
• Asymmetric Dimethylarginine Causes Hypertension and Cardiac Dysfunction in Humans and Is Actively Metabolized by Dimethylarginine Dimethylaminohydrolase

  2003cited by this paper
• Regulation of Cytokine-Induced Nitric Oxide Synthesis by Asymmetric Dimethylarginine: Role of Dimethylarginine Dimethylaminohydrolase

  2003cited by this paper
• Common genetic variation in a basal promoter element alters DDAH2 expression in endothelial cells.

  2003cited by this paper
• Distribution of nitric oxide synthases and nitrotyrosine in the kidney of spontaneously hypertensive rats

  2003cited by this paper
• Endothelial Dysfunction as a Predictor of Acute Coronary Syndromes

  2003cited by this paper
• Asymmetric Dimethylarginine Causes Hypertension and Cardiac Dysfunction in Humans and Is Actively Metabolized by Dimethylarginine Dimethylaminohydrolase

  2003cited by this paper
• Peroxisome Proliferator-Activated Receptor &ggr; Ligands Increase Release of Nitric Oxide From Endothelial Cells

  2003cited by this paper
• all-trans-Retinoic Acid Increases Nitric Oxide Synthesis by Endothelial Cells: A Role for the Induction of Dimethylarginine Dimethylaminohydrolase

  2002cited by this paper
• Pleiotropic Actions of Peroxisome Proliferator-Activated Receptors in Lipid Metabolism and Atherosclerosis

  2002cited by this paper
• Structure, Endothelial Function, Cell Growth, and Inflammation in Blood Vessels of Angiotensin II–Infused Rats: Role of Peroxisome Proliferator–Activated Receptor-&ggr;

  2002cited by this paper
• Relationship between insulin resistance and an endogenous nitric oxide synthase inhibitor.

  2002cited by this paper
• Effects of aging and AT-1 receptor blockade on NO synthase expression and renal function in SHR.

  2002cited by this paper
• Asymmetric dimethylarginine (ADMA): a potential link between endothelial dysfunction and cardiovascular diseases in insulin resistance syndrome?

  2002cited by this paper
• Troglitazone improves endothelial function and augments renal klotho mRNA expression in Otsuka Long-Evans Tokushima Fatty (OLETF) rats with multiple atherogenic risk factors.

  2001cited by this paper
• Peroxisome proliferator-activated receptor gamma ligands inhibit retinoblastoma phosphorylation and G1--> S transition in vascular smooth muscle cells.

  2000cited by this paper
• Long-term follow-up of patients with mild coronary artery disease and endothelial dysfunction.

  2000cited by this paper
• Study on the relationship between plasma nitrite and nitrate level and salt sensitivity in human hypertension : modulation of nitric oxide synthesis by salt intake.

  2000cited by this paper
• Peroxisome Proliferator-activated Receptor γ Ligands Inhibit Retinoblastoma Phosphorylation and G1 → S Transition in Vascular Smooth Muscle Cells*

  2000cited by this paper
• LDL cholesterol upregulates synthesis of asymmetrical dimethylarginine in human endothelial cells: involvement of S-adenosylmethionine-dependent methyltransferases.

  2000cited by this paper
• Does ADMA cause endothelial dysfunction?

  2000cited by this paper
• Reduced urinary excretion of nitric oxide metabolites and increased plasma levels of asymmetric dimethylarginine in men with essential hypertension.

  1999cited by this paper
• Zonal heterogeneity in action of angiotensin-converting enzyme inhibitor on renal microcirculation: role of intrarenal bradykinin.

  1999cited by this paper
• Metabolic, hemodynamic, and cardiac effects of captopril in young, spontaneously hypertensive rats.

  1999cited by this paper
• Altered pressure-natriuresis in obese Zucker rats.

  1999cited by this paper
• Asymmetric dimethylarginine (ADMA): a novel risk factor for endothelial dysfunction: its role in hypercholesterolemia.

  1998cited by this paper
• Upregulation of renal and vascular nitric oxide synthase in young spontaneously hypertensive rats.

  1998cited by this paper
• Hypoglycemic and hypotensive effects of 6-cyclohexyl-2'-O-methyl-adenosine, an adenosine A1 receptor agonist, in spontaneously hypertensive rat complicated with hyperglycemia.

  1998cited by this paper
• Biochemical evidence for impaired nitric oxide synthesis in patients with peripheral arterial occlusive disease.

  1997cited by this paper
• Asymmetrical dimethylarginine, an endogenous nitric oxide synthase inhibitor, in experimental hypertension.

  1997cited by this paper
• Long-term inhibition of NO synthesis promotes atherosclerosis in the hypercholesterolemic rabbit thoracic aorta : PGH[2] does not contribute to impaired endothelium-dependent relaxation

  1997cited by this paper
• Derangements of the nitric oxide synthase pathway, L-arginine, and cardiovascular diseases.

  1997cited by this paper
• Elevated L-arginine/dimethylarginine ratio contributes to enhanced systemic NO production by dietary L-arginine in hypercholesterolemic rabbits.

  1996cited by this paper
• Regulation of nitric oxide synthesis by dimethylarginine dimethylaminohydrolase

  1996cited by this paper
• A novel in vivo assay system for consecutive measurement of brain nitric oxide production combined with the microdialysis technique.

  1994cited by this paper
• Mechanism of compensatory hyperinsulinemia in normoglycemic insulin-resistant spontaneously hypertensive rats. Augmented enzymatic activity of glucokinase in beta-cells.

  1994cited by this paper
• Long-term inhibition of NO synthesis promotes atherosclerosis in the hypercholesterolemic rabbit thoracic aorta. PGH2 does not contribute to impaired endothelium-dependent relaxation.

  1994cited by this paper
• High Performance Liquid Chromatography Method for Rapid and Accurate Determination of Homocysteine in Plasma and Serum

  1991cited by this paper

• [DDAH1 protein: biological functions, role in carcinogenesis processes].

  2025cites this paper
• Decoding the anti-hypertensive mechanism of α-mangostin based on network pharmacology, molecular docking and experimental validation

  2024cites this paper
• Diabetic Nephropathy and Gaseous Modulators

  2023cites this paper
• Asymmetric Dimethylarginine (ADMA) in Pediatric Renal Diseases: From Pathophysiological Phenomenon to Clinical Biomarker and Beyond

  2021cites this paper
• The role of immune cells in pulmonary hypertension: Focusing on macrophages.

  2021cites this paper
• Pathophysiological roles of ADMA-mediated endothelial injury in hypertensive disorders of pregnancy

  2020cites this paper
• Asymmetric (ADMA) and Symmetric (SDMA) Dimethylarginines in Chronic Kidney Disease: A Clinical Approach

  2019cites this paper
• Uremic Toxin-Targeting as a Therapeutic Strategy for Preventing Cardiorenal Syndrome.

  2019cites this paper
• A functional variant of the dimethylarginine dimethylaminohydrolase-2 gene is associated with myocardial infarction in type 2 diabetic patients

  2019cites this paper
• Treatment with combination of pioglitazone and glimepiride decreases levels of chemerin and asymmetric dimethylarginine (ADMA) in obese type 2 diabetic patients

  2018cites this paper
• Nephroprotective effects of nebivolol in 2K1C rats through regulation of the kidney ROS-ADMA-NO pathway

  2018cites this paper
• Is pulmonary vascular disease reversible with PPAR ɣ agonists?

  2018cites this paper
• Toxic Dimethylarginines: Asymmetric Dimethylarginine (ADMA) and Symmetric Dimethylarginine (SDMA)

  2017cites this paper
• Sympathetic Overactivity in Chronic Kidney Disease: Consequences and Mechanisms

  2017cites this paper
• Serum trans fatty acids, asymmetric dimethylarginine and risk of acute myocardial infarction and mortality in patients with suspected coronary heart disease: a prospective cohort study

  2016cites this paper
• Asymmetric Dimethylarginine (ADMA) Levels Are Lower in Hemodialysis Patients Treated With Paricalcitol

  2016cites this paper
• Effect of Certain Pharmacotherapies on Plasma Asymmetric Dimethyl Arginine ( ADMA

  2016cites this paper
• Inhibitors of the Hydrolytic Enzyme Dimethylarginine Dimethylaminohydrolase (DDAH): Discovery, Synthesis and Development

  2016cites this paper
• The effects of atorvastatin on antioxidant/antiinflammatory properties of HDLs in hypercholesterolemics.

  2015influential citation
• Asymmetric dimethylarginine is associated with carotid atherosclerosis in patients with essential hypertension

  2015cites this paper
• Asymmetric dimethylarginine, a biomarker of cardiovascular complications in diabetes mellitus.

  2015cites this paper
• Asymmetric Dimethylarginine: Clinical Significance and Novel Therapeutic Approaches.

  2015cites this paper
• Modulating DDAH/NOS Pathway to Discover Vasoprotective Insulin Sensitizers

  2015cites this paper
• Rho-kinase contributes to pressure-induced constriction of renal microvessels.

  2014cites this paper
• Pioglitazone enhances the blood pressure-lowering effect of losartan via synergistic attenuation of angiotensin II-induced vasoconstriction

  2014cites this paper
• Role of asymmetric dimethylarginine in cardiorenal syndrome.

  2014cites this paper
• ADMA metabolism and chronic hypoxia-induced pulmonary hypertenstion

  2014cites this paper
• The current approach into signaling pathways in pulmonary arterial hypertension and their implication in novel therapeutic strategies

  2014cites this paper
• Clinical Evaluation of Extracellular ADMA Concentrations in Human Blood and Adipose Tissue

  2014cites this paper
• Untersuchung der Umsetzung asymmetrisch methylierter Argininedurch rekombinant hergestellte und native Dimethylarginin-Dimethylaminohydrolase-2

  2014cites this paper
• Calycosin and formononetin from astragalus root enhance dimethylarginine dimethylaminohydrolase 2 and nitric oxide synthase expressions in Madin Darby Canine Kidney II cells

  2013cites this paper
• Pioglitazone Decreases Asymmetric Dimethylarginine Levels in Patients with Impaired Glucose Tolerance or Type 2 Diabetes

  2013cites this paper
• Effects of Pioglitazone on Asymmetric Dimethylarginine and Components of the Metabolic Syndrome in Nondiabetic Patients (EPICAMP Study): A Double-Blind, Randomized Clinical Trial

  2013cites this paper
• Asymmetric Dimethylarginine and Endothelial Dysfunction

  2013cites this paper
• Cardiovascular risk in autoimmune disorders: role of asymmetric dimethylarginine.

  2012cites this paper
• Pioglitazone treatment increases COX‐2‐derived prostacyclin production and reduces oxidative stress in hypertensive rats: role in vascular function

  2012influential citation
• Nitric Oxide Manipulation: A Therapeutic Target for Peripheral Arterial Disease?

  2012cites this paper
• Rosiglitazone Affects Nitric Oxide Synthases and Improves Renal Outcome in a Rat Model of Severe Ischemia/Reperfusion Injury

  2012cites this paper
• The impact of pioglitazone on ADMA and oxidative stress markers in patients with type 2 diabetes.

  2012cites this paper
• 10. Asymmetric Dimethylarginine

  2012cites this paper
• Omega-3 Status and the Relationship between Plasma Asymmetric Dimethylarginine and Risk of Myocardial Infarction in Patients with Suspected Coronary Artery Disease

  2012influential citation
• Aktivität und Expression der plazentaren Dimethylarginin-Dimethylaminohydrolase bei gesunden Schwangeren und Frauen mit Präeklampsie

  2012cites this paper
• Asymmetric Dimethylarginine, an Endogenous NOS Inhibitor, Is Actively Metabolized in Rat Erythrocytes

  2012cites this paper
• Koroner arter hastalığının yaygınlığı ve ciddiyeti ile serum asimetrik dimetilarjinin düzeyi arasındaki ilişki

  2012cites this paper
• cAMP Phosphodiesterase Inhibitors Increases Nitric Oxide Production by Modulating Dimethylarginine Dimethylaminohydrolases

  2011cites this paper
• Effects of eicosapentaenoic acid on asymmetric dimethylarginine in patients in the chronic phase of cerebral infarction: a preliminary study.

  2011cites this paper
• Regulación por PPARy de la expresión vascular de COX-2 Y la producción de especies reactivas de oxigeno en hipertensión

  2011cites this paper
• Mechanisms of disease: pulmonary arterial hypertension

  2011cites this paper
• Advances in the Management of Pediatric Pulmonary Hypertension

  2011cites this paper
• Pediatric pulmonary arterial hypertension: current and emerging therapeutic options

  2011cites this paper
• PPARγ Dependence Of the Cyclosporine‐Isoprenaline Renovascular Interaction: Roles of Nitric Oxide Synthase And Heme Oxygenase

  2011cites this paper
• cAMP Phosphodiesterase Inhibitors Increases Nitric Oxide Production by Modulating Dimethylarginine Dimethylaminohydrolases

  2011cites this paper
• Pioglitazone delays proximal tubule dysfunction and improves cerebral vessel endothelial dysfunction in normoalbuminuric people with type 2 diabetes mellitus.

  2011cites this paper
• Asymmetric dimethylarginine: clinical applications in pediatric medicine.

  2011cites this paper
• The therapeutic potential of targeting endogenous inhibitors of nitric oxide synthesis

  2011cites this paper
• Serum asymmetric dimethylarginine levels in diabetic patients with neuropathy.

  2011cites this paper
• Increased plasma level of asymmetric dimethylarginine in hypertensive rats facilitates platelet aggregation: role of plasma tissue factor.

  2011cites this paper
• Pharmacological interventions on asymmetric dimethylarginine, a clinical marker of vascular disease.

  2011cites this paper
• Is peroxisome proliferator-activated receptor gamma (PPARγ) a therapeutic target for the treatment of pulmonary hypertension?

  2011influential citation
• The biology and therapeutic potential of the DDAH/ADMA pathway.

  2010cites this paper
• Ex vivo gene transferring of human dimethylarginine dimethylaminohydrolase-2 improved endothelial dysfunction in diabetic rat aortas and high glucose-treated endothelial cells.

  2010cites this paper
• Modulating the NO generating system from a medicinal chemistry perspective: current trends and therapeutic options in cardiovascular disease.

  2010cites this paper
• Does Peroxisome Proliferator-activated Receptor-γ (PPARγ) Protect from Hypertension Directly through Effects in the Vasculature?*

  2010cites this paper
• Regulation of the ADMA-DDAH system in endothelial cells: a novel mechanism for the sterol response element binding proteins, SREBP1c and -2.

  2010cites this paper
• Asymmetric Dimethylarginine Synthesis and Degradation Under Physiological and Pathological Conditions

  2010cites this paper
• Effect of selected drugs on plasma asymmetric dimethylarginine (ADMA) levels.

  2010cites this paper
• Role of PPARγ/Nitric Oxide Synthase Signaling in the Cyclosporine-induced Attenuation of Endothelium-dependent Renovascular Vasodilation

  2010cites this paper
• The Role of Asymmetric Dimethylarginine (ADMA) in Endothelial Dysfunction and Cardiovascular Disease

  2010cites this paper
• PPARgamma and the pathobiology of pulmonary arterial hypertension.

  2010cites this paper
• PPARγ Activation: A Potential Treatment For Pulmonary Hypertension

  2009cites this paper
• Therapeutic targets in pulmonary arterial hypertension.

  2009influential citation
• 15-Deoxy-Δ12,14-Prostaglandin J2 Upregulates the Expression of LPS-Induced IL-8/CXCL8 mRNA in Vascular Smooth Muscle Cells from Spontaneously Hypertensive Rats

  2009cites this paper
• Thiazolidinediones in Peritoneal Dialysis Patients

  2009cites this paper
• Tie2-mediated loss of peroxisome proliferator-activated receptor-gamma in mice causes PDGF receptor-beta-dependent pulmonary arterial muscularization.

  2009influential citation
• Dimethylarginine dimethylaminohydrolase regulation: a novel therapeutic target in cardiovascular disease

  2009cites this paper
• LPS-Induced IL-8/CXCL8 mRNA in Vascular Smooth Muscle Cells from Spontaneously Hypertensive Rats

  2009cites this paper
• Habilitationsschrift The Protective Role of PPAR γ in Pulmonary Arterial Hypertension

  2009cites this paper
• Tie2-mediated loss of peroxisome proliferator-activated receptor- (cid:1) in mice causes PDGF receptor- (cid:2) -dependent pulmonary arterial muscularization

  2009influential citation
• Tie2-mediated loss of peroxisome proliferator-activated receptor- (cid:1) in mice causes PDGF receptor- (cid:2) -dependent pulmonary arterial muscularization

  2009influential citation
• Drugs designed to improve endothelial function: effects on erectile dysfunction.

  2008cites this paper
• Cardiovascular disease, chronic kidney disease, and type 2 diabetes mellitus: proceeding with caution at a dangerous intersection.

  2008cites this paper
• Effects of pioglitazone on erectile dysfunction in sildenafil poor-responders: a randomized, controlled study.

  2008cites this paper
• An antiproliferative BMP-2/PPARgamma/apoE axis in human and murine SMCs and its role in pulmonary hypertension.

  2008cites this paper
• Diabetes Care capillaries and tubulointerstitial fibrosis in rats with chronic kidney

  2008cites this paper
• Asymmetrisches Dimethylarginin (ADMA): Ein kardiovaskulärer Risikofaktor

  2008cites this paper
• Angiotensin II Type 1 Receptor and Peroxisome Proliferator Activated Receptor Asymmetrical Dimethylarginine System : Role of − Effect of Telmisartan on Nitric Oxide

  2008cites this paper
• ADMA, cardiovascular disease and diabetes.

  2008cites this paper
• Role of asymmetric dimethylarginine in cardiovascular disease and diabetes.

  2008cites this paper
• Pioglitazone, a Thiazolidinedione Derivative, Attenuates Left Ventricular Hypertrophy and Fibrosis in Salt-Sensitive Hypertension

  2008cites this paper
• Nitric Oxide Upregulates Dimethylarginine Dimethylaminohydrolase-2 via Cyclic GMP Induction in Endothelial Cells

  2008cites this paper
• Role of asymmetric dimethylarginine (ADMA) in diabetic vascular complications.

  2008cites this paper
• Anti-hypertensive effects of Rosuvastatin are associated with decreased inflammation and oxidative stress markers in hypertensive rats

  2008cites this paper
• Pioglitazone Enhances the Antihypertensive and Renoprotective Effects of Candesartan in Zucker Obese Rats Fed a High-Protein Diet

  2008cites this paper
• Effect of Telmisartan on Nitric Oxide–Asymmetrical Dimethylarginine System: Role of Angiotensin II Type 1 Receptor and Peroxisome Proliferator Activated Receptor γ Signaling During Endothelial Aging

  2008cites this paper
• Antiproteinuric and anti‐inflammatory effects of thiazolidinedione (Review Article)

  2008cites this paper
• Peroxisome Proliferator-Activated Receptor-γ (PPAR-γ) Agonists Attenuate the Profibrotic Response Induced by TGF-β1 in Renal Interstitial Fibroblasts

  2007cites this paper
• Asymmetric dimethylarginine may be a missing link between cardiovascular disease and chronic kidney disease (Review Article)

  2007cites this paper
• From Zanius to ADMA: ADMA - a new ''adipocytokine'' and its potential role in metabolic syndrome.

  2007cites this paper
• Role of nitric oxide-producing and -degrading pathways in coronary endothelial dysfunction in chronic kidney disease.

  2007cites this paper
• Rosiglitazone prevents free fatty acid-induced vascular endothelial dysfunction.

  2007cites this paper